1st Jul 2014 10:21
LONDON (Alliance News) - Cyprotex PLC said Tuesday that it had expanded its capabilities at the BioHub site at Alderley Park, adding new scientific instruments to expand its offering to pharmaceuticals customers and potentially allowing it to enter new markets.
The company has added new instruments including at Waters Xevo G2-S QT high resolution accurate mass spectrometer, a LabLogic Beta-Ram radiochemical detector, and a Waters Atmospheric Pressure Gas Chromatography system.
The extra capabilities provided by the new instruments could potentially provide a route into new markets for Cyprotex such as personal care and chemicals.
The company said that whilst its current equipment is suitable for most of the molecules it tests, it is not appropriate for some compounds and chemicals as it moves into these new markets.
"As we expand into new markets we are observing a shift in the requirements for bioanalysis, and we are adapting our business accordingly," said Chief Executive Anthony Baxter in a statement. "We now have a wide range of solutions to cover our differing customers' needs, allowing us to grow our existing business as well as attract customers from new markets."
Alderley park is currently a research facility for AstraZeneca PLC. Its BioHub facilities provide office and laboratory space for biotechnology and life sciences businesses.
Shares in Cyprotex were trading down 3.7% at 6.50 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L